Luca Arcaini
About
Luca Arcaini is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology.
According to data from OpenAlex, Luca Arcaini has authored 223 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Pathology and Forensic Medicine, 117 papers in Genetics and 75 papers in Oncology. Recurrent topics in Luca Arcaini's work include Lymphoma Diagnosis and Treatment (125 papers), Chronic Lymphocytic Leukemia Research (80 papers) and Viral-associated cancers and disorders (52 papers). Luca Arcaini is often cited by papers focused on Lymphoma Diagnosis and Treatment (125 papers), Chronic Lymphocytic Leukemia Research (80 papers) and Viral-associated cancers and disorders (52 papers). Luca Arcaini collaborates with scholars based in Italy, United States and France. Luca Arcaini's co-authors include Mario Lazzarino, Francesco Passamonti, Cristiana Pascutto, Mario Cazzola, Emanuela Boveri, Marco Paulli, Elisa Rumi, Daniela Pietra, Matteo Giovanni Della Porta and Michele Merli and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Luca Arcaini
212 papers receiving 8.6k citations
Hit Papers
Peers
Luca Arcaini
Mario Lazzarino Italy
Francesco Zaja Italy
Pierre Morel France
Réda Bouabdallah France
David J. Inwards United States
Uday Popat United States
Chor Sang Chim China
Edie Weller United States
N. Niederle Germany
Francesco Rodeghiero Italy
Citations per year, relative to Luca Arcaini Luca Arcaini (= 1×)
peers
Mario Lazzarino
Countries citing papers authored by Luca Arcaini
Since
Specialization
Citations
This map shows the geographic impact of Luca Arcaini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Arcaini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Arcaini more than expected).
Fields of papers citing papers by Luca Arcaini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Luca Arcaini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Arcaini. The network helps show where Luca Arcaini may publish in the future.
Co-authorship network of co-authors of Luca Arcaini
This figure shows the co-authorship network connecting the top 25 collaborators of Luca Arcaini. A scholar is included among the top collaborators of Luca Arcaini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Arcaini. Luca Arcaini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Luminari, Stefano, Annalisa Chiappella, Alice Di Rocco, et al.. (2025). Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus. Cytotherapy. 27(11). 1316–1325.
2.
Marchetti, Monia, Paolo Corradini, Luca Arcaini, et al.. (2025). A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection. Hematological Oncology. 43(5). e70125–e70125.
3.
Lucioni, Marco, Giuseppe Neri, Erica Travaglino, et al.. (2024). Interleukin‐6 transcripts up‐regulation in lymph nodes from unicentric and multicentric Castleman disease. SHILAP Revista de lepidopterología. 5(6). 1182–1189.
4.
Barcellini, Amelia, Manuel Gotti, Luca Arcaini, et al.. (2024). Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before. Hematological Oncology. 42(3). e3269–e3269.
5.
Villasboas, José C., Stephen D. Smith, Carlos Grande, et al.. (2024). Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).. Journal of Clinical Oncology. 42(16_suppl). 7058–7058.
6.
Borsani, Oscar, Daniela Pietra, Ilaria Carola Casetti, et al.. (2023). Germline MPL mutations may be a rare cause of “triple-negative” thrombocytosis. Experimental Hematology. 129. 104127–104127.
7.
Lucioni, Marco, Giovanni Santacroce, Arturo Bonometti, et al.. (2023). Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas. Cancers. 15(10). 2743–2743.
8.
Lucioni, Marco, Arturo Bonometti, Chiara Moltrasio, et al.. (2021). Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes. Human Pathology. 111. 1–9.
9.
Bonometti, Arturo, Luca Diamanti, Matteo Paoletti, et al.. (2021). Hodgkin Lymphoma With Diplopia and Nystagmus: A Paraneoplastic Cerebellar Degeneration With Ectopic Expression of DNER Antigen on Reed-Sternberg Cells. Clinical Lymphoma Myeloma & Leukemia. 22(2). e124–e127.
10.
Merli, Michele, Irene Defrancesco, Carlo Visco, et al.. (2020). Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leukemia & lymphoma. 61(9). 2122–2128.
11.
Defrancesco, Irene, Silvia Zibellini, Emanuela Boveri, et al.. (2020). Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis. Hematological Oncology. 38(5). 689–697.
12.
Defrancesco, Irene, Sara Rattotti, Michele Merli, et al.. (2020). HCV infection and non-Hodgkin lymphomas: an evolving story. Clinical and Experimental Medicine. 20(3). 321–328.
13.
Varettoni, Marzia, Silvia Zibellini, Emanuela Boveri, et al.. (2019). A risk‐stratification model based on the initial concentration of the serum monoclonal protein and MYD 88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. British Journal of Haematology. 187(4). 441–446.
14.
Anastasia, Antonella, Annalisa Chiarenza, Luigi Marcheselli, et al.. (2019). Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL ). British Journal of Haematology. 185(4). 713–717.
15.
Zuccaro, Valentina, Andrea Lombardi, Erika Asperges, et al.. (2019). The Possible Role of Gut Microbiota and Microbial Translocation Profiling During Chemo-Free Treatment of Lymphoid Malignancies. International Journal of Molecular Sciences. 20(7). 1748–1748.
16.
Scudeller, Luigia, et al.. (2019). ICA-EMA: A Tool for Assessing Nursing Complexity of Patients with Oncohematologic Disease in an Italian Center. Creative Nursing. 25(2). 157–168.
17.
Defrancesco, Irene & Luca Arcaini. (2017). Overview on the management of non-gastric MALT lymphomas. Best Practice & Research Clinical Haematology. 31(1). 57–64.
18.
Arcaini, Luca, Thierry Lamy, Jan Walewski, et al.. (2017). Prospective subgroup analyses of the randomized MCL ‐002 (SPRINT ) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology. 180(2). 224–235.
19.
Federico, Massimo, Stefano Luminari, Alessandra Dondi, et al.. (2012). R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). American Journal of Clinical Oncology.
20.
Berto, Patrizia, Stefania Lopatriello, Luca Arcaini, et al.. (2007). Costo-efficacia di rituximab nella terapia di mantenimento in soggetti affetti da linfoma non-Hodgkin follicolare refrattario. IRIS Research product catalog (Sapienza University of Rome). 9(1). 9–19.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mario Lazzarino Breakdown of academic impact, for papers by Francesco Zaja Breakdown of academic impact, for papers by Pierre Morel Breakdown of academic impact, for papers by Réda Bouabdallah Breakdown of academic impact, for papers by David J. Inwards Breakdown of academic impact, for papers by Uday Popat Breakdown of academic impact, for papers by Chor Sang Chim Breakdown of academic impact, for papers by Edie Weller Breakdown of academic impact, for papers by N. Niederle Breakdown of academic impact, for papers by Francesco Rodeghiero